Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Arcus Biosciences (NYSE:RCUS) with a Buy and raises the price target from $44 to $45.
Login to comment